Scarica l'app Stockscreener
16.93
0.18%
-0.03
Dopo l'orario di chiusura:
16.93
Precedente Chiudi:
$16.96
Aprire:
$17.25
Volume 24 ore:
805.27K
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.04B
Reddito:
$13.73M
Utile/perdita netta:
$-114.48M
Rapporto P/E:
-9.1921
EPS:
-1.8418
Flusso di cassa netto:
$-78.49M
1 W Prestazione:
+3.87%
1M Prestazione:
-14.06%
6M Prestazione:
+14.08%
1 anno Prestazione:
-27.37%
Intervallo 1D:
$16.84
$17.29
Intervallo di 1 settimana:
$16.16
$17.56
Portata 52W:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
16.93 | 996.53M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-24 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-04-20 | Downgrade | Barclays | Overweight → Underweight |
| 2026-04-15 | Downgrade | UBS | Buy → Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Is First Patient Dosed Altering The Investment Case For Janux Therapeutics (JANX)? - Simply Wall Street
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey - Yahoo Finance
(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX) - Seeking Alpha
Here's Why You Should Add JANX Stock to Your Portfolio Now - Eastern Progress
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know - Eastern Progress
Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:JANX) 2026-09-17 - Seeking Alpha
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux - Yahoo Finance
4 Prostate Cancer Drug Stocks to Watch During Awareness Month - finance.yahoo.com
Janux doses first patient in JANX013 prostate cancer trial By Investing.com - Investing.com India
Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate - marketscreener.com
Janux Therapeutics doses first patient in Phase 1 study: Will JANX hold $17.07 support? - Traders Union
Janux doses first patient in JANX013 prostate cancer trial - Investing.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 - Yahoo Finance Australia
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX - TipRanks
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data - Investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Clinical-Stage ProgressPost-Earnings Drift - dars.gov.et
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
JANX Q2 2026 Earnings: Narrower Loss Beats Consensus, Shares Gain 3.5%EPS Miss Report - dars.gov.et
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Janux Therapeutics Inc Azioni (JANX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr |
Jun 02 '26 |
Sale |
14.03 |
4,059 |
56,944 |
75,941 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):